Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a Phase 3 study titled ‘A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma.’ The study aims to assess the effectiveness of etentamig, an investigational drug, against standard therapies in treating relapsed or refractory multiple myeloma, a challenging blood cancer.
The study tests etentamig administered intravenously as a monotherapy against standard available therapies, which include combinations like carfilzomib with dexamethasone and others. The goal is to determine if etentamig can improve patient outcomes compared to existing treatments.
This interventional study is randomized with a parallel assignment model and no masking, focusing primarily on treatment. It involves around 380 participants across 140 global sites, comparing two groups: one receiving etentamig and the other standard therapies.
The study began on November 28, 2023, with an estimated completion date in 2025. The last update was submitted on August 25, 2025, indicating ongoing recruitment and data collection.
This study could significantly impact AbbVie’s market position by potentially introducing a new treatment option for multiple myeloma. Positive results might boost investor confidence and influence stock performance, especially in comparison to competitors in the oncology space.
The study is currently recruiting, with further details available on the ClinicalTrials portal.